EVALUATING NON-AIDS INFECTIOUS DISEASE CONTROL MEASURES

本合同的总体目标是评估控制措施， 艾滋病以外的其他传染病。 仍然有许多传染病 有效和高度安全的疫苗和治疗方法已经 有待开发。 此外，对于某些疾病， 需要在目前没有的年龄组预防感染和疾病 保护，这将提高安全性。 新疫苗和药物 候选人继续发展，受到基础知识进步的推动， 以理工科为重 评估这些新的和改进的疫苗的能力， 以有效和迅速的方式治疗候选人是必不可少的 微生物学和传染病科的努力的一部分， 美国国家过敏和传染病研究所（National Institute of Allergy and Infectious Diseases，DMID） 疾病（NIAID）。 本疫苗和治疗评价合同 VTEU是这些努力的一个组成部分，支持第一阶段和 细菌和病毒疫苗的II期临床试验，其他 生物制品和药物作为预防和治疗措施， 所有年龄和风险类别的人都有传染病。 在选定 在这种情况下，还可以进行第三阶段疫苗试验。 评价很 重要的是病原体的流行病学监测， 对NIAID有特殊兴趣，并有能力开展有限的、相关的、 与疫苗生物学直接相关的基础和临床前研究， 免疫学

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). This contract for a Vaccine and Treatment Evaluation Unit [VTEU] is an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.